Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N. Takehara K, et al. Among authors: matsumoto t. J Gynecol Oncol. 2021 Mar;32(2):e21. doi: 10.3802/jgo.2021.32.e21. Epub 2021 Jan 6. J Gynecol Oncol. 2021. PMID: 33470063 Free PMC article. Clinical Trial.
Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group.
Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, Matsumoto T, Kita T, Takizawa K; Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group. Mikami M, et al. Among authors: matsumoto t. Int J Gynecol Cancer. 2013 Nov;23(9):1655-60; quiz 1661-2. doi: 10.1097/IGC.0000000000000005. Int J Gynecol Cancer. 2013. PMID: 24172100
Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
Takano T, Otsuki T, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, Niikura H, Ito K, Yaegashi N, Yamada H, Tase T, Kagabu M, Shoji T, Sugiyama T, Sato N, Fujimoto T, Terada Y, Nakahara K, Kurachi H, Yokoyama Y, Mizunuma H, Soeda S, Nishiyama H, Matsumoto T, Sato S, Shimada M, Kigawa J. Takano T, et al. Among authors: matsumoto t. Int J Clin Oncol. 2014 Dec;19(6):1052-8. doi: 10.1007/s10147-013-0658-y. Epub 2014 Jan 7. Int J Clin Oncol. 2014. PMID: 24395448 Clinical Trial.
Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: a survey of the Japanese Gynecologic Oncology Group.
Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, Matsumoto T, Kita T, Takizawa K; Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group. Mikami M, et al. Among authors: matsumoto t. Int J Gynecol Cancer. 2014 Sep;24(7):1333-40. doi: 10.1097/IGC.0000000000000202. Int J Gynecol Cancer. 2014. PMID: 25078340
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S, Nishio S, Okada S, Otsuki T, Fujiwara K, Tanabe H, Takano M, Hasumi Y, Takei Y, Hasegawa T, Matsumoto T, Fujiwara K, Takekuma M, Nakamura K, Shimada M, Suzuki M, Kigawa J. Nagao S, et al. Among authors: matsumoto t. Cancer Chemother Pharmacol. 2015 Aug;76(2):335-42. doi: 10.1007/s00280-015-2793-9. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092322
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T, Takeshima N, Sugiyama T. Komiyama S, et al. Among authors: matsumoto t. Int J Clin Oncol. 2019 Jan;24(1):103-114. doi: 10.1007/s10147-018-1319-y. Epub 2018 Jul 20. Int J Clin Oncol. 2019. PMID: 30030657 Free PMC article.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I. Fujiwara K, et al. Among authors: matsumoto t. J Gynecol Oncol. 2021 Sep;32(5):e82. doi: 10.3802/jgo.2021.32.e82. J Gynecol Oncol. 2021. PMID: 34378365 Free PMC article. Clinical Trial.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. Among authors: matsumoto k, matsumoto t. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Free PMC article. Clinical Trial.
10,247 results
You have reached the last available page of results. Please see the User Guide for more information.